Form 4: Director Sells ELVN Shares Under 10b5-1 Plan

Enliven Therapeutics Director Richard A. Heyman sold 1,230 shares of common stock for $26.1759 per share under a pre-arranged trading plan.

Summary

• Richard A. Heyman, a Director of Enliven Therapeutics, Inc. (ELVN), reported a sale of common stock.
• The transaction involved the disposition of 1,230 shares of common stock.
• The shares were sold at a weighted average price of $26.1759 per share.
• The sale was executed on February 17, 2026.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.
• Following the transaction, Heyman beneficially owns 123,673 shares directly, 22,647 shares indirectly through the Heyman Daigle Trust, and 25,545 shares indirectly through RAHD Capital LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be perceived negatively, the transaction was conducted under a pre-arranged Rule 10b5-1 plan, which mitigates concerns about opportunistic trading based on non-public information.

Negatives

• A director selling shares, even under a Rule 10b5-1 plan, could be perceived negatively by some market participants, potentially suggesting a lack of confidence.

Risks

• Potential for negative market perception or investor sentiment due to insider selling, despite the transaction being executed under a pre-arranged Rule 10b5-1 plan.

Future Outlook

This filing does not contain any forward-looking statements or guidance from the company regarding its operations or financial performance.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is a routine disclosure for publicly traded companies. While it doesn't necessarily signal a negative outlook, investors often scrutinize such transactions for insights into management's confidence, especially when compared to broader market trends or peer activity in the biotechnology sector.

Comparison to Industry Standards

• This Form 4 filing is standard for reporting insider transactions. The execution of sales under a Rule 10b5-1 plan is a common practice among executives in various industries, including biotechnology, to manage personal finances while adhering to insider trading regulations.
• Without specific industry benchmarks for director selling activity, a direct comparison to other biotechnology companies like Amgen or Gilead Sciences on the volume or frequency of insider sales would require more context on their respective 10b5-1 plans and overall insider holdings.

Related Party Transactions

• The Rule 10b5-1 trading plan, under which the shares were sold, was adopted by the Reporting Person (Richard A. Heyman) and the Richard A. Heyman and Anne E. Daigle Trust, for which the Reporting Person serves as trustee.
• Indirect beneficial ownership of 22,647 shares is held by the Heyman Daigle Trust.
• Indirect beneficial ownership of 25,545 shares is held by RAHD Capital LLC, for which the Reporting Person serves as a managing member.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a slight negative signal, though the execution under a Rule 10b5-1 plan reduces its significance and suggests a pre-planned financial management activity rather than a reaction to new information.

Key Dates

Recommendation

The filing reports a routine insider sale by a director under a pre-arranged 10b5-1 plan. This type of transaction is common for personal financial management and does not typically indicate a change in the company's fundamental outlook or warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as this event alone does not provide new information to alter an existing investment decision.

Keywords

Enliven Therapeutics, ELVN, Form 4, Insider Trading, Stock Sale, Director, Richard A. Heyman, 10b5-1 Plan